Showing 1821 - 1840 of 3461 results
The mining industry is set to benefit from a new Australian capability that uses a nuclear scanning technique to detect the presence of precious metals and strategic minerals in a core sample.
NSW grants bolster additive manufacturing and groundwater processing capabilities.
Neutron Capture Enhanced Particle Therapy developed at ANSTO.
Australia is as a member of the Generation IV International Forum (GIF), a cooperative international endeavour, involving the participation of 12 other nations and the European Union to work together on long term research on advanced nuclear technologies.
Grant supports development of handheld technology to verify origin of seafood.
Dr Luiz Bortolan Neto, a structural materials engineer at ANSTO has received an Industry Partnership award for his significant contribution to defence science at the DMTC annual conference in Canberra, last week.
Beamtime guide on the SAX / WAXS beamline at the Australian Synchrotron.
Researchers and industry partners from UNSW Australia, the Australian Centre for Nanomedicine, Children’s Cancer Institute and Inventia Life Sciences Pty Ltd have been awarded the 2021 ANSTO Eureka Prize for Innovative Use of Technology for their method to rapidly-produce 3D cell structures
The Australian Synchrotron has played a crucial role in the discovery of a new cancer drug for the treatment of leukaemia.
ANSTO is a major supplier of Australia’s radioactive isotopes used in nuclear medicine, delivering around 10,000 patient doses each week. Health-based research and development in Australia and overseas also benefit greatly from ANSTO’s unique capabilities and expertise in the detection, diagnosis and treatment of disease using nuclear and accelerator infrastructure.
Experiments at the Synchrotron enable researchers to produce a 3D structure of a molecular scaffold with role in cancer
Melbourne researchers have used the Australian Synchrotron to produce structure of molecule known to play a critical role in the development and spread of aggressive cancer.
International fusion researchers, including ANSTO’s Dr Richard Garrett, have recently returned from ITER in France where they attended a meeting of the coordinating committee of the International Tokomak Physics Activity (ITPA).
International fusion researchers recently returned from ITER in France where they attended a meeting of the coordinating committee of the International Tokomak Physics Activity.
A targeted radioactive infusion that is a game-changer in late-stage prostate cancer can also dramatically improve outcomes for patients in earlier stages of this disease, a Peter Mac-led study has shown.
With the screening of the popular HBO series about Chernobyl, we asked our Nuclear Analysis team for their insights on key differences between the reactor in the TV series, a Generation II RBMK power reactor and ANSTO’s state of the art research reactor OPAL.
Update on Nuclear medicine production at ANSTO.